Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Boehringer Ingelheim
Express Scripts
AstraZeneca
Mallinckrodt

Last Updated: June 28, 2022

CLINICAL TRIALS PROFILE FOR ELUXADOLINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Eluxadoline

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01130272 ↗ Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea Completed Furiex Pharmaceuticals, Inc Phase 2 2010-04-28 The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea (IBS-d).
NCT01553591 ↗ Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) Completed Furiex Pharmaceuticals, Inc Phase 3 2012-05-29 The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.
NCT01553747 ↗ Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) Completed Furiex Pharmaceuticals, Inc Phase 3 2012-05-29 The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.
NCT02959983 ↗ Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use Completed Allergan Phase 4 2016-10-25 This study will evaluate the efficacy and safety of eluxadoline 100 milligrams (mg) twice a day (BID) versus placebo for the treatment of patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) who report that the use of loperamide in the prior 12 months failed to provide control of their IBS-D symptoms.
NCT03339128 ↗ Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children Recruiting Allergan Phase 2 2017-11-15 The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years of age, to evaluate the pharmacokinetics of eluxadoline in pediatric participants with IBS-D, and to evaluate the safety and tolerability of eluxadoline in pediatric participants with IBS-D.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Eluxadoline

Condition Name

Condition Name for Eluxadoline
Intervention Trials
Irritable Bowel Syndrome 5
Diarrhea 2
Irritable Bowel Syndrome With Diarrhea 2
Fecal Incontinence 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Eluxadoline
Intervention Trials
Diarrhea 9
Syndrome 7
Irritable Bowel Syndrome 7
Urinary Incontinence, Urge 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Eluxadoline

Trials by Country

Trials by Country for Eluxadoline
Location Trials
United States 176
Canada 11
United Kingdom 11
Poland 4
Italy 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Eluxadoline
Location Trials
Oklahoma 6
Illinois 5
Arkansas 5
Texas 5
California 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Eluxadoline

Clinical Trial Phase

Clinical Trial Phase for Eluxadoline
Clinical Trial Phase Trials
Phase 4 2
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Eluxadoline
Clinical Trial Phase Trials
Completed 5
Recruiting 3
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Eluxadoline

Sponsor Name

Sponsor Name for Eluxadoline
Sponsor Trials
Allergan 5
Furiex Pharmaceuticals, Inc 3
University of North Carolina, Chapel Hill 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Eluxadoline
Sponsor Trials
Industry 8
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Dow
Boehringer Ingelheim
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.